Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9211 |
High Similarity |
NPD5283 |
Phase 1 |
0.9035 |
High Similarity |
NPD228 |
Approved |
0.886 |
High Similarity |
NPD3022 |
Approved |
0.886 |
High Similarity |
NPD3021 |
Approved |
0.873 |
High Similarity |
NPD3027 |
Phase 3 |
0.8699 |
High Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.8385 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.8385 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.8254 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.813 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.8106 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.8077 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.807 |
Intermediate Similarity |
NPD3020 |
Approved |
0.8 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7983 |
Intermediate Similarity |
NPD2684 |
Approved |
0.797 |
Intermediate Similarity |
NPD1613 |
Approved |
0.797 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7967 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7955 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7955 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.7955 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.7895 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7869 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7857 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7836 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7829 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7829 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.782 |
Intermediate Similarity |
NPD3144 |
Approved |
0.782 |
Intermediate Similarity |
NPD3145 |
Approved |
0.7807 |
Intermediate Similarity |
NPD2859 |
Approved |
0.7807 |
Intermediate Similarity |
NPD2860 |
Approved |
0.7752 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7744 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7727 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7727 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7719 |
Intermediate Similarity |
NPD2933 |
Approved |
0.7719 |
Intermediate Similarity |
NPD9296 |
Approved |
0.7719 |
Intermediate Similarity |
NPD2934 |
Approved |
0.768 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7674 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7669 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7664 |
Intermediate Similarity |
NPD6896 |
Approved |
0.7664 |
Intermediate Similarity |
NPD6895 |
Approved |
0.7656 |
Intermediate Similarity |
NPD2668 |
Approved |
0.7656 |
Intermediate Similarity |
NPD2667 |
Approved |
0.7652 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7643 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7623 |
Intermediate Similarity |
NPD5451 |
Approved |
0.7615 |
Intermediate Similarity |
NPD2232 |
Approved |
0.7615 |
Intermediate Similarity |
NPD2233 |
Approved |
0.7615 |
Intermediate Similarity |
NPD2230 |
Approved |
0.7594 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7589 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7589 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7589 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7556 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7538 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7537 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.7521 |
Intermediate Similarity |
NPD968 |
Approved |
0.7519 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7519 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7519 |
Intermediate Similarity |
NPD4624 |
Approved |
0.7519 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7518 |
Intermediate Similarity |
NPD3657 |
Discovery |
0.7518 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD1283 |
Approved |
0.75 |
Intermediate Similarity |
NPD2922 |
Phase 1 |
0.7482 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7482 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7462 |
Intermediate Similarity |
NPD3847 |
Discontinued |
0.7442 |
Intermediate Similarity |
NPD1651 |
Approved |
0.744 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7431 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7429 |
Intermediate Similarity |
NPD2161 |
Phase 2 |
0.7426 |
Intermediate Similarity |
NPD5718 |
Phase 2 |
0.7424 |
Intermediate Similarity |
NPD1669 |
Approved |
0.7424 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7424 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7414 |
Intermediate Similarity |
NPD1432 |
Clinical (unspecified phase) |
0.7413 |
Intermediate Similarity |
NPD5241 |
Discontinued |
0.7394 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7394 |
Intermediate Similarity |
NPD4162 |
Approved |
0.7391 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7388 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7324 |
Intermediate Similarity |
NPD4664 |
Clinical (unspecified phase) |
0.7319 |
Intermediate Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.7317 |
Intermediate Similarity |
NPD290 |
Approved |
0.7299 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7293 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7293 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7288 |
Intermediate Similarity |
NPD288 |
Approved |
0.7273 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7273 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7273 |
Intermediate Similarity |
NPD3092 |
Approved |
0.7273 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7273 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7267 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7266 |
Intermediate Similarity |
NPD709 |
Approved |
0.726 |
Intermediate Similarity |
NPD1754 |
Clinical (unspecified phase) |
0.7255 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7254 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7254 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7246 |
Intermediate Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7239 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7231 |
Intermediate Similarity |
NPD3091 |
Approved |
0.7231 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7226 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7222 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7222 |
Intermediate Similarity |
NPD6658 |
Clinical (unspecified phase) |
0.7219 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7219 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7219 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7218 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7218 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.7218 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7214 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7211 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7203 |
Intermediate Similarity |
NPD2808 |
Discontinued |
0.7203 |
Intermediate Similarity |
NPD844 |
Approved |
0.7194 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7194 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.719 |
Intermediate Similarity |
NPD291 |
Approved |
0.7185 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7185 |
Intermediate Similarity |
NPD3055 |
Approved |
0.7185 |
Intermediate Similarity |
NPD3053 |
Approved |
0.7183 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7177 |
Intermediate Similarity |
NPD1358 |
Approved |
0.7176 |
Intermediate Similarity |
NPD5585 |
Approved |
0.7176 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7174 |
Intermediate Similarity |
NPD2028 |
Clinical (unspecified phase) |
0.7172 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7165 |
Intermediate Similarity |
NPD9377 |
Approved |
0.7165 |
Intermediate Similarity |
NPD7635 |
Approved |
0.7165 |
Intermediate Similarity |
NPD821 |
Approved |
0.7165 |
Intermediate Similarity |
NPD9379 |
Approved |
0.7163 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7163 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7163 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7153 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD37 |
Approved |
0.7143 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7133 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7133 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7133 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7133 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7133 |
Intermediate Similarity |
NPD7028 |
Phase 2 |
0.7132 |
Intermediate Similarity |
NPD6387 |
Discontinued |
0.7124 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7122 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7122 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.7113 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7111 |
Intermediate Similarity |
NPD5311 |
Approved |
0.7111 |
Intermediate Similarity |
NPD5310 |
Approved |
0.7109 |
Intermediate Similarity |
NPD2234 |
Approved |
0.7109 |
Intermediate Similarity |
NPD2228 |
Approved |
0.7109 |
Intermediate Similarity |
NPD2229 |
Approved |
0.7107 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7107 |
Intermediate Similarity |
NPD289 |
Clinical (unspecified phase) |
0.7105 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7103 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7101 |
Intermediate Similarity |
NPD2669 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD3134 |
Approved |
0.7095 |
Intermediate Similarity |
NPD7527 |
Clinical (unspecified phase) |
0.7095 |
Intermediate Similarity |
NPD52 |
Approved |
0.7095 |
Intermediate Similarity |
NPD7526 |
Approved |
0.7092 |
Intermediate Similarity |
NPD6353 |
Approved |
0.7092 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7092 |
Intermediate Similarity |
NPD4579 |
Clinical (unspecified phase) |
0.7083 |
Intermediate Similarity |
NPD7037 |
Approved |
0.7078 |
Intermediate Similarity |
NPD7833 |
Phase 2 |
0.7078 |
Intermediate Similarity |
NPD7832 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD7831 |
Phase 2 |
0.7077 |
Intermediate Similarity |
NPD3596 |
Phase 2 |
0.7075 |
Intermediate Similarity |
NPD7041 |
Phase 2 |
0.7075 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7075 |
Intermediate Similarity |
NPD7040 |
Clinical (unspecified phase) |
0.7071 |
Intermediate Similarity |
NPD2979 |
Phase 3 |
0.7068 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7067 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7063 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7063 |
Intermediate Similarity |
NPD1792 |
Phase 2 |
0.7063 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.7063 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7059 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7059 |
Intermediate Similarity |
NPD987 |
Approved |
0.7055 |
Intermediate Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.705 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7045 |
Intermediate Similarity |
NPD4093 |
Discontinued |
0.7042 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7037 |
Intermediate Similarity |
NPD3685 |
Discontinued |
0.7037 |
Intermediate Similarity |
NPD3676 |
Clinical (unspecified phase) |
0.7034 |
Intermediate Similarity |
NPD845 |
Approved |
0.7031 |
Intermediate Similarity |
NPD1138 |
Approved |
0.7027 |
Intermediate Similarity |
NPD4584 |
Approved |
0.702 |
Intermediate Similarity |
NPD6875 |
Approved |
0.702 |
Intermediate Similarity |
NPD6876 |
Approved |
0.7015 |
Intermediate Similarity |
NPD1535 |
Discovery |
0.7013 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7013
|
Intermediate Similarity |
NPD4967 |
Phase 2 |